Douglas Ingram

2017

In 2017, Douglas Ingram earned a total compensation of $56.9M as President and Chief Executive Officer at Sarepta Therapeutics.

Compensation breakdown

Non-Equity Incentive Plan$420,875
Option Awards$44,484,000
Salary$337,500
Stock Awards$11,607,750
Other$16,116
Total$56,866,241

Ingram received $44.5M in option awards, accounting for 78.23% of the total pay in 2017.

Ingram also received $420.9K in non-equity incentive plan, $337.5K in salary, $11.6M in stock awards and $16.1K in other compensation.

Overall ranking

Ranking

20

out of 13,853
Percentile100th

Douglas Ingram's 2017 compensation ranked 20th out of 13,853 executive pay records tracked by us this year.

Ingram earned more than 99.9% of all executives tracked by us in 2017.

Ranking in industry group

Industry groupDrugs
Ranking

1

out of 1,584
Percentile100th

In the industry group of Drugs, Ingram's pay ranked 1st out of 1,584 executive pay records tracked by us in 2017.

Ingram earned more than 99.9% of executives in this group.

Source: SEC filing on April 26, 2018.

Ingram's colleagues

We found six more compensation records of executives who worked with Douglas Ingram at Sarepta Therapeutics in 2017.

2017

Edward Kaye

Sarepta Therapeutics

Chief Executive Officer

2017

Guriqbal Basi

Sarepta Therapeutics

Chief Scientific Officer

2017

Alexander Cumbo

Sarepta Therapeutics

Senior Vice President, Chief Commercial Officer

2017

Sandesh Mahatme

Sarepta Therapeutics

Chief Financial Officer

2017

David Howton

Sarepta Therapeutics

General Counsel

2017

Catherine Stehman-Breen

Sarepta Therapeutics

Chief Medical Officer

News

In-depth

You may also like